Purdue, execs plead guilty to misbranding OxyContin, agree to $634.5M fine
Compliance Monitor, May 16, 2007
Want to receive articles like this one in your inbox? Subscribe to Compliance Monitor!
Purdue Pharma and its president, chief legal officer, and former chief medical officer pleaded guilty last week to misbranding OxyContin, the company's highly addictive painkiller, according to the Department of Justice (DOJ). In addition to the guilty pleas, the company and the executives will pay $634.5 million in fines, including $160 million to cover false claims liability.
Purdue and the three executives pleaded guilty to fraudulently claiming that OxyContin was less addictive and less subject to abuse than it actually is. They also fraudulently claimed that the drug was less likely to cause withdrawal symptoms than other pain medications, although the company had no scientific evidence to support those claims and no FDA approval to make them.
The guilty plea follows a $19.5 million settlement with 26 states and the District of Columbia to settle claims that Purdue encouraged physicians to overprescribe OxyContin, reports the Associated Press.
According to the DOJ, the misbranding scheme involved several components, including:
To read more about the settlement and guilty plea, visit the DOJ Web site.
Want to receive articles like this one in your inbox? Subscribe to Compliance Monitor!
Related Products
Most Popular
- Articles
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- Identify potential Medicaid RAC target areas
- HIPAA Q&A: Level of encryption needed for email
- Topic: CMS, OESS post new security compliance review information, checklist
- Capturing all necessary codes for IUD insertion and removal can be challenging
- What does case-mix index mean to you?
- OB services: Coding inside and outside of the package
- QA:Coding multiple initial infusions
- E-mailed
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- HIPAA Q&A: Level of encryption needed for email
- Q&A: Follow CMS' coding guidelines when using modifier -25
- What does case-mix index mean to you?
- Catch up on what's new with injections and infusions
- CMS has reformulated payments for some bilateral procedures
- New conflicts of interest create new challenges
- Q/A. One injection code or two?
- ED-to-inpatient transfers are flawed with safety gaps
- Searched
